Back to search
FDAFDA · Food and drugs·Recall number D-1537-2020

Dexmedetomidine HCl in 0.9% Sodium Chloride Injection, 200 mcg per 50 mL (4 mcg per mL), for intravenous infusion, preservative free, 50 mL Single Dose Bottle, Rx only, Fresenius Kabi Lake Zurich, IL 60047, NDC 63323-671-05

Published September 2, 2020 · Recall initiated: July 22, 2020

Summary

FDA records drug Class I recall D-1537-2020, published September 2, 2020 and initiated July 22, 2020. Recalling firm: Fresenius Kabi USA, LLC; Status: Terminated; Reported quantity: 25,100 bottles; Lot: Lot #: 6121853, Exp 05/2021; 6122207, Exp 06/2021. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Cross Contamination with other products: trace amounts of lidocaine

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Fresenius Kabi USA, LLC
Distributor
U.S.A. Nationwide
Lot
Lot #: 6121853, Exp 05/2021; 6122207, Exp 06/2021
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Dexmedetomidine HCl in 0.9% Sodium Chloride Injection, 200 mcg per 50 mL (4 mcg per mL), for intravenous infusion, preservative free, 50 mL Single Dose Bottle, Rx only, Fresenius Kabi Lake Zurich, IL 60047, NDC 63323-671-05 recalled?

Yes. FDA published recall D-1537-2020 on September 2, 2020. Reported hazard: Cross Contamination with other products: trace amounts of lidocaine

What should I do if I have this product?

Voluntary: Firm initiated · Press Release